{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T10:37:55Z","timestamp":1789641475099,"version":"4.0.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,1,6]],"date-time":"2015-01-06T00:00:00Z","timestamp":1420502400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,1,6]],"date-time":"2015-01-06T00:00:00Z","timestamp":1420502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1007\/s40265-014-0341-2","type":"journal-article","created":{"date-parts":[[2015,1,5]],"date-time":"2015-01-05T13:18:15Z","timestamp":1420463895000},"page":"183-196","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Simeprevir: A Review of Its Use in Patients with Chronic Hepatitis C Virus Infection"],"prefix":"10.1007","volume":"75","author":[{"given":"Mark","family":"Sanford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,1,6]]},"reference":[{"key":"341_CR1","unstructured":"World Health Organization. Hepatitis C fact sheet number 164. 2014. http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en\/. Accessed 6 August 2014."},{"issue":"Suppl. 2","key":"341_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1478-3231.2011.02537.x","volume":"31","author":"F Negro","year":"2011","unstructured":"Negro F, Alberti A. The global health burden of hepatitis C virus infection. Liver Int. 2011;31(Suppl. 2):1\u20133.","journal-title":"Liver Int."},{"issue":"4","key":"341_CR3","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1128\/AAC.01058-08","volume":"53","author":"T-I Lin","year":"2009","unstructured":"Lin T-I, Lenz O, Fanning G, et al. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob Agents Chemother. 2009;53(4):1377\u201385.","journal-title":"Antimicrob Agents Chemother."},{"issue":"7","key":"341_CR4","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/nm.3248","volume":"19","author":"TKH Scheel","year":"2013","unstructured":"Scheel TKH, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med. 2013;19(7):837\u201349.","journal-title":"Nat Med."},{"issue":"7","key":"341_CR5","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1093\/cid\/cir076","volume":"52","author":"BL Pearlman","year":"2011","unstructured":"Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C infection: a cure and so much more. Clin Infect Dis. 2011;52(7):889\u2013900.","journal-title":"Clin Infect Dis."},{"issue":"2","key":"341_CR6","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jhep.2013.11.003","volume":"60","author":"European Association for the Study of the Liver","year":"2014","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol. 2014;60(2):392\u2013420.","journal-title":"J Hepatol."},{"issue":"1","key":"341_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1055\/s-0034-1371007","volume":"34","author":"J-M Pawlotsky","year":"2014","unstructured":"Pawlotsky J-M. New hepatitis C virus (HCV) drugs and the hope for a cure: concepts in anti-HCV drug development. Semin Liver Dis. 2014;34(1):22\u20139.","journal-title":"Semin Liver Dis."},{"issue":"1","key":"341_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3851\/IMP2125","volume":"23","author":"E Thomas","year":"2012","unstructured":"Thomas E, Ghany MG, Liang TJ. The application and mechanism of action of ribavirin in therapy of hepatitis C. Antivir Chem Chemother. 2012;23(1):1\u201312.","journal-title":"Antivir Chem Chemother."},{"issue":"5","key":"341_CR9","doi-asserted-by":"publisher","first-page":"619","DOI":"10.2165\/11208370-000000000-00000","volume":"72","author":"CM Perry","year":"2012","unstructured":"Perry CM. Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C. Drugs. 2012;72(5):619\u201341.","journal-title":"Drugs."},{"issue":"18","key":"341_CR10","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.2165\/11209560-000000000-00000","volume":"72","author":"KP Garnock-Jones","year":"2012","unstructured":"Garnock-Jones KP. Boceprevir: a review of its use in the management of chronic hepatitis C genotype 1 infection. Drugs. 2012;72(18):2431\u201356.","journal-title":"Drugs."},{"issue":"12","key":"341_CR11","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1136\/gutjnl-2012-302910","volume":"61","author":"G Dusheiko","year":"2012","unstructured":"Dusheiko G, Wedemeyer H. New protease inhibitors and direct-acting antivirals for hepatitis C: interferon\u2019s long goodbye. Gut. 2012;61(12):1647\u201352.","journal-title":"Gut."},{"issue":"Suppl 1","key":"341_CR12","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/liv.12424","volume":"34","author":"T Asselah","year":"2014","unstructured":"Asselah T, Marcellin P. Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir. Liver Int. 2014;34(Suppl 1):60\u20138.","journal-title":"Liver Int."},{"issue":"3","key":"341_CR13","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/MOG.0000000000000062","volume":"30","author":"ML Shiffman","year":"2014","unstructured":"Shiffman ML. Hepatitis C virus therapy in the direct acting antiviral era. Curr Opin Gastroenterol. 2014;30(3):217\u201322.","journal-title":"Curr Opin Gastroenterol."},{"key":"341_CR14","unstructured":"European Medicines Agency. Daklinza 30\u00a0mg film-coated tablets: summary of product characteristics. 2014. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003768\/WC500172848.pdf. Accessed 9 Sep 2014."},{"issue":"10","key":"341_CR15","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s40265-014-0247-z","volume":"74","author":"GM Keating","year":"2014","unstructured":"Keating GM. Sofosbuvir: a review of its use in patients with chronic hepatitis C. Drugs. 2014;74(10):1127\u201346.","journal-title":"Drugs."},{"key":"341_CR16","unstructured":"European Medicines Agency. Olysio 150 mg hard capsules: summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002777\/WC500167867.pdf. Accessed 10 Dec 2014."},{"key":"341_CR17","unstructured":"Janssen-Cilag. OLYSIOTM (simeprevir) capsules, for oral use: US prescribing Information. 2013. http:\/\/www.olysio.com\/shared\/product\/olysio\/prescribing-information.pdf. Accessed 20 Nov 2014."},{"key":"341_CR18","unstructured":"Medivir AB. Simeprevir has been approved in Japan for the treatment of genotype 1 chronic hepatitis C infection [media release]. 27 September 2013. http:\/\/www.medivir.com."},{"key":"341_CR19","unstructured":"Medivir AB. Simeprevir has been approved in Canada as a new treatment for hepatitis C [media release]. 20 November 2013. http:\/\/www.cision.com."},{"issue":"18","key":"341_CR20","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1007\/s40265-013-0153-9","volume":"73","author":"A Vaidya","year":"2013","unstructured":"Vaidya A, Perry CM. Simeprevir: first global approval. Drugs. 2013;73(18):2093\u2013106.","journal-title":"Drugs."},{"issue":"5","key":"341_CR21","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1128\/AAC.01452-09","volume":"54","author":"O Lenz","year":"2010","unstructured":"Lenz O, Verbinnen T, Lin TI, et al. In vitro resistance profile of the hepatitis C virus NS3\/4A protease inhibitor TMC435. Antimicrob Agents Chemother. 2010;54(5):1878\u201387.","journal-title":"Antimicrob Agents Chemother."},{"issue":"3","key":"341_CR22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/cld.332","volume":"3","author":"MV Lin","year":"2014","unstructured":"Lin MV, Chung R. Recent FDA approval of sofosbuvir and simeprevir. Implications for current HCV treatment. Clin Liver Dis. 2014;3(3):65\u20138.","journal-title":"Clin Liver Dis."},{"issue":"9","key":"341_CR23","doi-asserted-by":"publisher","first-page":"4417","DOI":"10.1128\/AAC.00399-13","volume":"57","author":"G Kalkeri","year":"2013","unstructured":"Kalkeri G, Lin C, Gopilan J, et al. Restoration of the activated Rig-I pathway in hepatitis C virus (HCV) replicon cells by HCV protease, polymerase, and NS5A inhibitors in vitro at clinically relevant concentrations. Antimicrob Agents Chemother. 2013;57(9):4417\u201326.","journal-title":"Antimicrob Agents Chemother."},{"issue":"6","key":"341_CR24","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/j.jhep.2011.12.033","volume":"56","author":"C Moreno","year":"2012","unstructured":"Moreno C, Berg T, Tanwandee T, et al. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. J Hepatol. 2012;56(6):1247\u201353.","journal-title":"J Hepatol."},{"key":"341_CR25","doi-asserted-by":"publisher","first-page":"S139","DOI":"10.1016\/S0168-8278(14)60383-4","volume":"1","author":"O Lenz","year":"2014","unstructured":"Lenz O, Verbinnen T, Fevery B, et al. Virology analyses of simeprevir in phase 2b and 3 studies [abstract no. P221]. J Hepatol. 2014;1:S139\u201340.","journal-title":"J Hepatol"},{"key":"341_CR26","first-page":"S416","volume":"52","author":"V Sekar","year":"2010","unstructured":"Sekar V, Vis P, Lenz O, et al. Pharmacokinetic\u2013pharmacodynamic (PK-PD) analyses of TMC435 in treatment-naive hepatitis C (HCV)-infected patients in the OPERA-1 study [abstract no. P1075]. J Hepatol. 2010;52:S416.","journal-title":"J Hepatol."},{"key":"341_CR27","doi-asserted-by":"crossref","unstructured":"Ouwerkerk-Mahadevan S, Simion A, Spittaels K, et al. Pharmacokinetics of simeprevir (TMC435) in volunteers with moderate or severe hepatic impairment [abstract no. 887]. J Hepatol. 2013;58(Suppl. 1):S365. Plus poster presented at the 48th Annual Meeting of the European Association for the Study of the Liver; 24\u201328 April 2013; Amsterdam.","DOI":"10.1016\/S0168-8278(13)60889-2"},{"key":"341_CR28","unstructured":"Ouwerkerk-Mahadevan S, Sekar V, Simion A, et al. The pharmacokinetic interactions of HCV protease inhibitor TMC435 with antiretroviral agents in healthy volunteers [abstract no. 1618 with poster]. ID Week; 17\u201321 October 2012; San Diego (CA)."},{"issue":"Suppl. 1","key":"341_CR29","first-page":"565A","volume":"56","author":"S Ouwerkerk-Mahadevan","year":"2012","unstructured":"Ouwerkerk-Mahadevan S, Beumont M, Spittaels KF, et al. No pharmacokinetic interaction between the investigational HCV protease inhibitor TMC435 and an oral contraceptive containing ethinylestradiol and norethindrone [abstract no. 773]. Hepatology. 2012;56(Suppl. 1):565A\u20136A.","journal-title":"Hepatology."},{"issue":"7","key":"341_CR30","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.3851\/IMP1894","volume":"16","author":"M Manns","year":"2011","unstructured":"Manns M, Reesink H, Berg T, et al. Rapid viral response of once-daily TMC435 plus pegylated interferon\/ribavirin in hepatitis C genotype-1 patients: a randomized trial. Antivir Ther. 2011;16(7):1021\u201333.","journal-title":"Antivir Ther."},{"issue":"6","key":"341_CR31","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1002\/hep.26641","volume":"58","author":"MW Fried","year":"2013","unstructured":"Fried MW, Buti M, Dore GJ, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study. Hepatology. 2013;58(6):1918\u201329.","journal-title":"Hepatology."},{"issue":"1","key":"341_CR32","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s00535-013-0875-1","volume":"49","author":"N Hayashi","year":"2014","unstructured":"Hayashi N, Seto C, Kato M, et al. Once-daily simeprevir (TMC435) with peginterferon\/ribavirin for treatment-naive hepatitis C genotype 1-infected patients in Japan: the DRAGON study. J Gastroenterol. 2014;49(1):138\u201347.","journal-title":"J Gastroenterol."},{"key":"341_CR33","doi-asserted-by":"crossref","unstructured":"Zeuzem S, Berg T, Gane E, et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology. 2014;146(2):430\u201341.e6.","DOI":"10.1053\/j.gastro.2013.10.058"},{"issue":"5","key":"341_CR34","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00535-014-0949-8","volume":"49","author":"N Izumi","year":"2014","unstructured":"Izumi N, Hayashi N, Kumada H, et al. Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies. J Gastroenterol. 2014;49(5):941\u201353.","journal-title":"J Gastroenterol."},{"issue":"9941","key":"341_CR35","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S0140-6736(14)60494-3","volume":"384","author":"IM Jacobson","year":"2014","unstructured":"Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2014;384(9941):403\u201313.","journal-title":"Lancet."},{"issue":"9941","key":"341_CR36","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/S0140-6736(14)60538-9","volume":"384","author":"M Manns","year":"2014","unstructured":"Manns M, Marcellin P, Poordad F, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2014;384(9941):414\u201326.","journal-title":"Lancet."},{"issue":"2","key":"341_CR37","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jhep.2014.04.004","volume":"61","author":"N Hayashi","year":"2014","unstructured":"Hayashi N, Izumi N, Kumada H, et al. Simeprevir with peginterferon\/ribavirin for treatment-naive hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. J Hepatol. 2014;61(2):219\u201327.","journal-title":"J Hepatol."},{"key":"341_CR38","doi-asserted-by":"crossref","unstructured":"Forns X, Lawitz E, Zeuzem S, et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology. 2014;146(7):1669\u201379 e3.","DOI":"10.1053\/j.gastro.2014.02.051"},{"key":"341_CR39","unstructured":"Reddy KR, Zeuzem S, Zoulim F, et al. A phase III randomised, double-blind study to evaluate the efficacy, safety and tolerability of simeprevir vs telaprevir in combination with pegylated interferon and ribavirin in chronic hepatitis C virus genotype 1 treatment-experienced patients: the ATTAIN study [abstract no. LB 1]. Hepatol Int. 2014;1:S397. Plus poster presented at the Asian Pacific Association for the Study of the Liver; 12\u201315 March 2014; Brisbane."},{"key":"341_CR40","doi-asserted-by":"publisher","unstructured":"Dieterich D, Rockstroh JK, Orkin C, et al. Simeprevir (TMC435) with peginterferon\/ribavirin in patients coinfected with HCV genotype-1 and HIV-1: a phase III study. Clin Infect Dis. 2014. doi:10.1093\/cid\/ciu675.","DOI":"10.1093\/cid\/ciu675"},{"key":"341_CR41","doi-asserted-by":"publisher","unstructured":"Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014. doi:10.1016\/S0140-6736(14)61036-9.","DOI":"10.1016\/S0140-6736(14)61036-9"},{"key":"341_CR42","doi-asserted-by":"publisher","first-page":"S495","DOI":"10.1016\/S0168-8278(14)61382-9","volume":"60","author":"E Lawitz","year":"2014","unstructured":"Lawitz E, Rodriguez-Torres M, Nguyen T, et al. A phase II study of samatasvir (IDX719) in combination with simeprevir and ribavirin in treatment-naive HCV-infected subjects with genotypes 1b and 4 (HELIX-1 study) [abstract no. P1222]. J Hepatol. 2014;60:S495\u20136.","journal-title":"J Hepatol"},{"key":"341_CR43","doi-asserted-by":"publisher","first-page":"S535","DOI":"10.1016\/S0168-8278(14)61486-0","volume":"60","author":"C Moreno","year":"2014","unstructured":"Moreno C, Hezode C, Marcellin P, et al. Once-daily simeprevir (TMC435) with peginterferon\/ribavirin in treatment-naive or treatment-experienced chronic HCV genotype 4-infected patients: final results of a phase III trial [abstract no. P1319]. J Hepatol. 2014;60:S535.","journal-title":"J Hepatol."},{"issue":"7","key":"341_CR44","doi-asserted-by":"publisher","first-page":"A362","DOI":"10.1016\/j.jval.2013.08.230","volume":"16","author":"J Scott","year":"2013","unstructured":"Scott J, Gilles L, Fu M, et al. Patients with chronic hepatitis C virus treated with simeprevir added to peginterferon and ribavirin experienced less time with fatigue, depressive symptoms, and functional limitations: results from patients in the QUEST-1, QUEST-2, and PROMISE studies [abstract no. PIN120]. Value Health. 2013;16(7):A362.","journal-title":"Value Health."},{"key":"341_CR45","unstructured":"World Health Organization. Guidelines for the screening, care and treatment of persons with hepatitis C infection. 2014. http:\/\/apps.who.int\/iris\/bitstream\/10665\/111747\/1\/9789241548755_eng.pdf?ua=1. Accessed 19 Aug 2014."},{"key":"341_CR46","unstructured":"European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C. 2014. http:\/\/www.easl.eu. Accessed 14 Aug 2014."},{"key":"341_CR47","unstructured":"American Association for the Study of Liver Diseases and Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. 2014. http:\/\/www.hcvguidelines.org. Accessed 21 Oct 2014."},{"issue":"12","key":"341_CR48","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1111\/apt.12764","volume":"39","author":"MH Miller","year":"2014","unstructured":"Miller MH, Agarwal K, Austin A, et al. Review article: 2014 UK consensus guidelines\u2014hepatitis C management and direct-acting anti-viral therapy. Aliment Pharmacol Ther. 2014;39(12):1363\u201375.","journal-title":"Aliment Pharmacol Ther."},{"issue":"Suppl 1","key":"341_CR49","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/liv.12408","volume":"34","author":"ML Shiffman","year":"2014","unstructured":"Shiffman ML, Benhamou Y. HCV F1\/F2 patients: treat now or continue to wait. Liver Int. 2014;34(Suppl 1):79\u201384.","journal-title":"Liver Int."},{"key":"341_CR50","unstructured":"European Medicines Agency. Sovaldi (sofosbuvir): EU summary of product characteristics. 2014. http:\/\/www.ema.europa.eu\/. Accessed 21 Aug 2014."},{"issue":"Suppl 1","key":"341_CR51","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1093\/infdis\/jis761","volume":"207","author":"DL Wyles","year":"2013","unstructured":"Wyles DL. Antiviral resistance and the future landscape of hepatitis C virus infection therapy. J Infect Dis. 2013;207(Suppl 1):S33\u20139.","journal-title":"J Infect Dis."},{"issue":"1","key":"341_CR52","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/hep.27151","volume":"60","author":"LM Hagan","year":"2014","unstructured":"Hagan LM, Sulkowski MS, Schinazi RF. Cost analysis of sofosbuvir\/ribavirin versus sofosbuvir\/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible\/intolerant individuals. Hepatology. 2014;60(1):37\u201345.","journal-title":"Hepatology."},{"key":"341_CR53","unstructured":"National Institute for Health and Care Excellence. Hepatitis C (chronic)-simeprevir. 2014. http:\/\/www.nice.org.uk\/Guidance\/InDevelopment\/GID-TAG455. Accessed 21 Aug."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-014-0341-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-014-0341-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-014-0341-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-014-0341-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T16:46:09Z","timestamp":1659113169000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-014-0341-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,6]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["341"],"URL":"https:\/\/doi.org\/10.1007\/s40265-014-0341-2","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,6]]},"assertion":[{"value":"6 January 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}